reports
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at ...
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the ® (SABCS). The company will share the latest advances in the that support guideline-driven treatment decisions. Additionally, the company is presenting data on its , an ul...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI ...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), and , today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leader...
Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET. The presentations will be available through live audio webcas...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Heredit...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs 100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced —the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical Oncology (ASCO). The...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 Nati...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among ...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterat...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Th...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to Ge...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner Faster initial remission and response, persistent benefit over six months SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disord...
Myriad Genetics to Release Third Quarter 2025 Financial Results on Nov...
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025. A live webcast of the conference call can be a...
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8 and FXN, to the . “At Myriad Genetics, we carefully design the Foresight panel to prioritize clinical significance, selecting genes based on condition severity, prevalence, actionability, and guidelines,” sai...
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion...
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global test...
Myriad Genetics Announces Precise MRD Clinical Data Published in The L...
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). One of the goals of this study was to determine whether patients with oligometastatic ccRCC could benefit from incorporating ultrasensitive MRD testing into t...
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can S...
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when ® Psychotropic test results were available to treating clinicia...
Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET. Links to the live and archived webcasts of both presentations can be viewed at . About ...
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scot...
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Rea...
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened—primarily...
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises ...
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-ov...
Myriad Genetics Announces New $200 Million Credit Facility
Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an additional $75 million until June 30, 2027. This facility matures on July 31, 2030, and bears interest at a rate based upon the one-mo...
Myriad Genetics to Release Second Quarter 2025 Financial Results on Au...
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025. A live webcast of the conference call can be ...
Myriad Genetics Earns 2025 Great Place To Work Certification™
Myriad Genetics Earns 2025 Great Place To Work Certification™ SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place To Work – 30 percentage points higher than the average U.S. company. “Our focus on inclusivity and caring makes this a great p...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prena...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will simultaneously delive...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.